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Background. Tumor irradiation combined with adjuvant treatments, either vascular targeted or immunomodulatory,
is under intense investigation. Gene electrotransfer of therapeutic genes is one of these approaches. The aim of this
study was to determine, whether gene electrotransfer of plasmid encoding shRNA for silencing endoglin, with vascular
targeted effectiveness, can radiosensitize melanoma B16F10 tumors.
Materials and methods. The murine melanoma B16F10 tumors, growing on the back of C57Bl/6 mice, were treated
by triple gene electrotransfer and irradiation. The antitumor effect was evaluated by determination of tumor growth
delay and proportion of tumor free mice. Furthermore, histological analysis of tumors (necrosis, apoptosis, proliferation, vascularization, presence of hypoxia and infiltration of immune cells,) was used to evaluate the therapeutic
mechanisms.
Results. Gene electrotransfer of plasmid silencing endoglin predominantly indicated vascular targeted effects of
the therapy, since significant tumor growth delay and 44% of tumor free mice were obtained. In addition, irradiation
had minor effects on radioresistant melanoma, with 11% of mice tumor free. The combined treatment resulted in excellent effectiveness with 88% of mice tumor free, with more than half resistant to secondary tumor challenge, which
was observed also with the plasmid devoid of the therapeutic gene. Histological analysis of tumors in the combined
treatment group, demonstrated similar mode of action of the gene electrotransfer of plasmid encoding shRNA for
silencing endoglin and devoid of it, both through the induction of an immune response.
Conclusions. The results of this study indicate that irradiation can in radioresistant melanoma tumors, by release of tumor associated antigens, serve as activator of the immune response, besides directly affecting tumor cells and vasculature. The primed antitumor immune response can be further boosted by gene electrotransfer of plasmid, regardless
of presence of the therapeutic gene, which was confirmed by the high radiosensitization, resulting in prolonged tumor
growth delay and 89% of tumor free mice that were up to 63% resistant to secondary challenge of tumor. In addition,
gene electrotransfer of therapeutic plasmid for silencing endoglin has also a direct effect on tumor vasculature and
tumors cells; however in combination with radiotherapy this effect was masked by pronounced immune response.
Key words: gene therapy; electrotransfer; plasmid, irradiation, immune response, melanoma

Introduction
Electroporation is used as drug delivery system
for molecules with hampered transmembrane
Radiol Oncol 2017; 51(1): 30-39.

transport.1 It is effective for delivery of smaller
molecules, as chemotherapeutics in electrochemotherapy (ECT)1-3 and also for larger molecules, as
are plasmids in gene electrotransfer (GET). GET is
doi:10.1515/raon-2017-0011
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recently getting a lot of scientific consideration and
it is used for enhanced DNA delivery into various
tissue types (i.e. skin, liver, kidney etc.), as well as
into tumors.4-6 Its effectiveness was first demonstrated in a wide range of preclinical studies and
has thereafter proceeded to clinical oncology, veterinary and human. The results of clinical trials of
GET of plasmid encoding human IL-127 and antiangiogenic plasmid AMEP8, are promising. In addition to GET of therapeutic plasmids, some plasmids
devoid of therapeutic genes have also resulted in
good antitumor effectiveness.9,10 This phenomenon
was observed in different tumors models and by
using different plasmids. It was attributed to immune sensing of the introduced DNA as a DAMP
(Damage Associated Molecular Pattern), which
switch leads to activation of an immune response.11
Radiotherapy is one of the principal treatment
modalities for primary tumors and their metastases.12 Nowadays, irradiation is widely investigated
for its associated effects on priming antitumor immunity.13 There is growing evidence of irradiation’s effect on the antitumor immune response,
inducing immunogenic cell death and generating
danger signals. An important danger signal after
irradiation is DNA released from the nucleus of dying cells. This DNA is recognized by the immune
system as a DAMP, and can promote the activation
of immune response against irradiated cells.14,15
Studies combining tumor irradiation with GET
of different therapeutic plasmid demonstrated tumor radiosensitization.16-18 A promising approach
to target tumors and its microenvironment with a
combined treatment modality is through destructing abnormal tumor blood vessels. One of the
promising targets, gaining on its value due to different signaling pathways from VEGF, is endoglin.
It is a TGF-β coreceptor and has already demonstrated good antitumor and antimetastatic effectiveness in different tumor models when targeted
with GET of plasmid.18–22 In particular, GET of
shRNA for silencing endoglin in B16F10 melanoma
mice tumors that express high levels of endoglin,
resulted in up to 58% of tumor cures.23
Tissue specific eukaryotic promoters are tightly
regulated and mainly drive expression of transgene
in specific cell types, although minimal unspecific
expression in non-targeted tissue can also occur.24
We constructed a plasmid containing a tissue specific promoter for endothelin and encoding shRNA
for silencing endoglin. This plasmid was tested in
a previous study, where the effectiveness of the
plasmid with tissue specific promoter was compared to a plasmid with constitutive promoter

in a tumor model that does not express targeted
molecule, endoglin. In vivo, the effectiveness of the
GET of the plasmids was comparable and resulted
in significant radiosensitization, which resulted in
prolonged tumor growth delay with nearly 50% of
tumor free mice. Thus, the aim of this current study
was to determine, whether GET of plasmid, with
tissue specific promoter and encoding shRNA for
silencing endoglin, can radiosensitize melanoma
B16F10 tumors, which express targeted molecule,
endoglin, and possibly have also some immunomodulatory effectiveness.

Materials and methods
Cell lines and plasmids
Murine melanoma cell line B16F10 (American
Type Culture Collection, Manassas, VA, USA)
was cultured in advanced minimum essential medium (AMEM, Gibco, Thermo Fisher Scientific,
Waltham, MA, USA) supplemented with 5% fetal
bovine serum (FBS, Gibco), 10 mM/L L-glutamine
(GlutaMAX, Gibco), 100 U/mL penicillin
(Grünenthal, Aachen, Germany) and 50 mg/mL
gentamicin (Krka, Novo mesto, Slovenia) in a 5%
CO2 humidified incubator at 37°C.
The plasmid with tissue specific promoter for
endothelial cells, encoding shRNA for silencing
endoglin (pET-antiCD105; TS plasmid) was used in
experiments as the therapeutic plasmid.18 The control plasmid, encoding shRNA with no homology to
any gene in the mouse genome and with constitutive CMV promoter, was used as a negative control
(pControl).25 Amplification of both plasmids was
performed in a competent E.coli (JM107; Invitrogen,
Thermo Fisher Scientific, Waltham, MA, USA).
All plasmids were isolated using JETSTAR
2.0 ENDOTOXIN-FREE Plasmid MEGA Kit
(Genomed, Löhne, Germany) and diluted in endotoxin free water to a concentration of 1 μg/μL (in vitro experiments) and 4 μg/μL (in vivo experiments).
Concentrations of plasmids were measured with a
spectrophotometer at 260 nm (Epoch Microplate
Spectrophotometer, Take3 Micro-Volume Plate,
BioTek, Bad Friedrichshall, Germany) and purity
of plasmid was determined by agarose gel electrophoresis and measurements of the absorbance
ratio at 260 and 280 nm.

Experimental animals
All animal experiments were conducted in accordance with the guidelines for animal experiments of
Radiol Oncol 2017; 51(1): 30-39.
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TABLE 1. Response of B16F10 melanoma to different treatment modalities

Therapeutic group

DT (days)
n

AM

CTRL

8

1.2

pControl

8

TS

8

3 × EP
3 × GET (pControl)

TGD (days)

TF

SC

SEM

AM

SEM

n

%

n

%

±

0.1

0.0

±

0.1

0

0

-

-

1.9

±

0.2

2.2

±

0.3

0.7

±

0.2

0

0

-

-

1.0

±

0.3

0

0

-

-

8

3.1

±

8

9.4

±

0.3

2.0

±

0.3

0

0

-

-

6.5

8.2

±

2.5

0

0

-

-

3 × GET (TS)

9

9.5

IR

9

1.8

±

3.2

8.6

±

3.0

4

44

3

75

±

0.3

0.7

±

0.3

0

0

-

-

pControl + IR

9

TS + IR

8

2.5

±

0.3

1.3

±

0.3

1

11

1

100

4.0

±

1.2

2.8

±

1.2

0

0

-

-

3 × EP+IR

9

4.3

±

1.3

3.2

±

1.3

2

22

0

0

3 × GET (pControl) + IR

9

36.0

±

n/a

34.9

±

n/a

8

89

5

63

3 × GET (TS) + IR

8

32.0

±

n/a

30.8

±

n/a

7

88

4

57

AM = Arithmetic mean; DT = Tumor doubling time; Groups: (CTRL = control; EP = electric pulses; GET = gene electrotransfer; IR = irradiation; TS = pETantiCD105); n = Number of all mice in the group; n/a = Not applicable; SC = Mice resistant to secondary challenge; SEM = Standard error; TF = Tumor
free mice; TGD = Tumor growth delay

the EU Directive and the permission obtained from
the Ministry of Agriculture and the Environment
of the Republic of Slovenia (Permission No. 344011/2015/16), which was given, based on the approval
of the National Ethics Committee for Experiments
on Laboratory Animals).
Female C57Bl/6 mice, 6-8-week old, purchased
from Envigo Laboratories (Udine, Italy), were
used in the study. Before the experiment, mice
were subjected to an adaptation period of 2 weeks.
Animals were maintained under specific pathogen-free conditions at a constant room temperature, humidity and a 12 h light/dark cycle. Food
and water were provided ad libitum. For induction
of subcutaneous tumors, a suspension of 1x106
B16F10 cells in 0.1 ml of physiological saline was
injected subcutaneously into the back of the mice.
The animals bearing tumors of 40 mm3 were randomly divided into experimental groups and subjected to a specific experimental protocol. The tumor measurements were completed when the tumors reached 350 mm3, and mice were humanely
sacrificed.
Experimental groups and the number of animals
in each of them were as follows and as described in
table Table 1: triple injection of endotoxin-free water alone (control group; CTRL) or of pControl or
TS plasmids alone, or in combination with triple
application of electric pulses alone (3 × EP) or combined with plasmids (3 × GET (pControl); 3 × GET
(TS)). Furthermore, the remaining groups were
Radiol Oncol 2017; 51(1): 30-39.

also the ones in combination with irradiation (IR)
and other therapies described above, which are
three injections of plasmids (pControl + IR; TS + IR)
and in combination with electric pulses (3 × EP +
IR; 3 × GET (pControl) + IR; 3 × GET (TS) + IR).

In vivo GET
In vivo GET of plasmid into subcutaneous tumors
was performed 3 times every second day (on days
0, 2 and 4). 12.5 μL (4 μg/μL) of plasmid (150 μg in
total) in endotoxin-free H2O was injected intratumorally 10 min before 8 square electric pulses with
a voltage-to-distance ratio of 600 V/cm, a pulse duration of 5 ms, and a frequency 1 Hz were applied.
Electric pulses were generated by electric pulse
generator ELECTRO CELL B10 (Betatech, L’Union,
France) and delivered through 2 parallel stainless
steel electrodes with 2 or 4 mm distance between
them, depending on the tumor volume. After 4
pulses, electrodes were turned for 90° for 4 additional pulses to assure GET to entire tumor.

Irradiation of tumors
Tumors were locally irradiated with a single dose
of 15 Gy on day 1 from the beginning of the experiment, at a dose rate of 2.16 Gy/min, using a Darpac
2000 X-ray unit (Gulmay Medical Ltd., Shepperton,
UK) operating at 220 kV, 10 mA, with 1.8-mm aluminum filtration. During irradiation, mice were
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FIGURE 1. Histological sections of melanoma tumors on day 6 after the beginning of the therapy.
CTRL = control; EP = electric pulses; GET = gene electrotransfer; IR = irradiation; TS = pET-antiCD105

restrained in special lead holders with apertures
for irradiation of the tumors. Due to the fixed size
of the apertures, some healthy tissue (3 – 5 mm of
skin surrounding the tumor) was exposed to the
irradiation as well.

Tumor growth
The therapeutic potential in vivo was assessed by
measuring the tumor size every second day and
calculating tumor volume according to the formula for ellipsoid: V=axbxc π/6, where a, b and c
represent perpendicular tumor diameters.21,26 The
tumor growth curves were drawn as arithmetic
means (AM) with bars representing standard errors (SEM).
The tumor growth delay for each experimental group was calculated as the difference in tumor doubling times of experimental and control
groups. Tumor doubling time is the number of
days in which the initial tumor volume (40-50 mm3)
doubles. Mice that remained tumor free for 70 days
were termed tumor free and local tumor control
was deemed to have been achieved (Table 1). The
weight of the mice was followed as a general index of systemic toxicity, and acute skin reaction in
the whole irradiated field around the tumor was
evaluated as described elsewhere.17

Tumor challenge of tumor free mice
After 70 days, when mice were designated as tumor free, they were challenged with a subcutaneous injection of 1 × 106 B16F10 cells in 0.1 ml of
physiological saline in the right flank. Mice that at
least 20 days after the challenge remained tumor
free were marked as resistant to secondary challenge (Table 1, Figure 2). The growing tumors were
measured twice a week and when volume of 150
mm3 was reached mice were sacrificed and tumors

were collected for further histological analysis as
described below.

Histology
After therapies, at day 6, three mice from each experimental group were sacrificed. The tumors were
excised, fixed in IHC zinc fixative (BD Biosciences,
San Diego, CA, USA) and embedded in paraffin.
Six consecutive 2-μm thick sections were cut from
each paraffin block and stained as followed. To
estimate the percent of the area of tumor necrosis, the first section was stained with hematoxylin
and eosin. The other five sections were used for
immunohistochemical (IHC) staining to evaluate
percentage of hypoxic cells, cells in apoptosis, immune cells, proliferating cells and the number of
blood vessels. To determine hypoxic cells, rabbit
polyclonal antibodies against HIF-1-alpha (ab2185,
Abcam, Cambridge, MA, USA) at dilution 1:3500,
were used. In addition, apoptosis was evaluated
with help of cleaved Caspase-3 (Asp175., Cell signaling Technology, Danvers, MA, USA) at dilution
1:1500, whereas immune cells (NK and CTL) were
stained with help of Granzyme B (ab4059, Abcam)
at dilution 1:1250. For staining proliferating cells,
rabbit monoclonal antibodies against Ki-67 (clone
SP6, Thermo Fisher Scientific) at dilution 1:1200
were used. The last section was stained for determination of the number of blood vessels, by using
primary rabbit polyclonal antibodies against CD31
(ab28364, Abcam) at dilution 1:1000. For these sections, a peroxidase-conjugated streptavidin–biotin
system (Rabbit specific HRP/DAB detection IHC
kit, ab64261, Abcam) was used as the colorogenic
reagent followed by hematoxylin counterstaining.
From each slide and each feature (apoptosis, hypoxia, proliferation, vascularisation and immune
cells), five randomly selected viable parts of each
tumor were observed and captured under the light
Radiol Oncol 2017; 51(1): 30-39.
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FIGURE 2. Immune response of melanoma tumors is observed by vitiligo effect.
CTRL = control; EP = electric pulses; GET = gene electrotransfer; IR = irradiation; TS = pET-antiCD105

microscopy, by DP72 CCD camera (Olympus,
Hamburg, Germany) connected to a BX-51 microscope (Olympus) under 40× magnification (numerical aperture 0.85). The viable parts were analyzed
in blind fashion and the results were presented
as the percent (hypoxia, apoptosis, proliferation)
of the cells or the number of cells (immune cells)
or the structures (vascularization) positive to IHC
staining. The percentage of necrosis was contributed to the tumors as whole and was also evaluated
in blind fashion, as previously described.18
In addition, tumors that grew up to 150 mm3 after
secondary challenge of tumors, were excised, fixed
and embedded in paraffin, as described above.
Furthermore, from each tumor sections were cut
Radiol Oncol 2017; 51(1): 30-39.

and stained with hematoxylin and eosin to determinate morphological changes of tumor cells.

Statistical analysis
All data were tested for normality of distribution with the Shapiro-Wilk test. The differences
between the experimental groups were statistically evaluated by one-way analysis of variance
(one-way ANOVA) followed by a Holm-Sidak test
for multiple comparison. A P-value of less than
0.05 was considered to be statistically significant.
SigmaPlot Software (Systat Software, Chicago, IL,
USA) was used for statistical analysis and graphical representation.
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Results
Gene electrotransfer of plasmid
silencing endoglin indicates a vascular
targeted effects of the therapy
GET of either plasmids (pControl, TS) to melanoma
tumors had statistically significant antitumor effectiveness compared to untreated tumors, which
resulted in 8.2 ± 2.5 and 8.6 ± 3.0 days of tumor
growth delay, respectively (Table 1). However,
GET (TS) resulted in 44% of tumor free mice and
75% of them were resistant to secondary challenge,
whereas in the GET (pControl) group no tumor free
mice were obtained. Histological analysis (Table 2)
of GET (TS) group demonstrated reduction of vascularization (14.9 ± 1.1%) and proliferating cells
(49.5 ± 3.8%), whereas hypoxia (46.3 ± 3.0%) levels were increased and statistically significant to
at least pertinent control groups (CTRL, pControl,
TS and 3 × GET (pControl)). The levels of necrosis,
apoptosis and number of infiltrating immune cells
in the tumors were comparable in both GET treatment modalities (Figure 1) and statistically significant to at least CTRL, pControl and TS. These results indicated the vascular targeted effects of the
GET (TS), used for silencing endoglin.

Irradiation, alone or combined
either with plasmids injection or
electric pulses, had minor effect on
radioresistant melanoma tumors
Irradiation monotherapy with 15 Gy had minor
effects on radioresistant melanoma tumor. The
tumor growth delay was moderate in the groups
of irradiation alone or in combination with injection of plasmids (from 0.7 ± 0.3 to 2.8 ± 1.2 days)
and up to 11% of tumor free mice were obtained
in the group of irradiation in combination with injection of plasmid pControl (Table 1). The results
of histological analysis (Table 2, Figure 1) indicates
an immunological effect of the irradiation alone or
in combination with plasmids injection, since the
number of infiltrating immune cells in the tumors
was statistically significantly higher in comparison
to control groups (CTRL, pControl, TS) and groups
applying electric pulses (alone or combined with
injection of plasmids (GET (pControl) and GET
(TS)), and the tumor free mice were resistant to secondary challenge. Furthermore, irradiation alone
caused the reduction in proliferating cell levels
(53.3 ± 3.5%) and in tumor vascularization (30.1 ±
2.3%), whereas apoptosis (18.4 ± 1.8%) and hypoxia (30.2 ± 2.4%) levels were elevated. All of these

results were statistically significant compared to
CTRL, pControl and TS groups.
The application of electric pulses to tumors in
combination with tumor irradiation resulted in better antitumor effectiveness than observed in each
of these two treatment modalities alone. The tumor
growth delay in combined treatment was 3.2 ± 1.3
days and 22% of tumor free mice were obtained
(Table 1). The histological analysis of combined
treatment demonstrated statistically significant
higher levels of apoptosis (31.0 ± 2.0%) and hypoxia
(51.7 ± 2.6%) in comparison to the groups of irradiation and electric pulses alone. Among these three
groups no statistically significant differences were
observed in the levels of necrosis. Furthermore, the
analysis of levels of proliferating cells, the number
of tumor blood vessels and immune cells infiltrating in the tumors, resulted in similar and moderate effectiveness of the combined treatment (3 ×
EP + IR) and irradiation (alone or combined with
injection of plasmids), which statistically significantly differed from group of electric pulses alone.
Nevertheless, in this combined treatment modality
(3 × EP + IR) no tumor free mice were resistant to
secondary challenge of tumors.

Combination of GET and irradiation
exerts pronounced antitumor effects
The groups combining GET of plasmids (pControl,
TS) and irradiation resulted in pronounced therapeutic effectiveness, with up to 89% and 88% of
tumor free mice, respectively, and from those up
to 63% and 57% of mice was resistant to secondary tumor challenge, respectively (Table 1). The
histological analysis, of tumors excised 6 days after
treatment (Table 2, Figure 1), indicated on similar
mode of action of these combined treatment modalities (3 × GET (pControl or TS) + IR), since the
elevation of necrosis (65.0 ± 7.6%, 79.2 ± 4.2%),
number of immune cells (45.8 ± 3.0%, 46.5 ± 2.1%),
reduction of tumor vascularization (18.9 ± 2.0%,
12.8 ± 1.0%) and proliferation (46.0 ± 4.8%, 46.7 ±
4.8%), did not differ between these groups. Only
two statistically significant differences between
the therapeutic groups combining GET (pControl,
TS) and irradiation were observed which were the
level of hypoxia (58.0 ± 2.8%, 66.7 ± 1.6%), and apoptosis (38.7 ± 3.1%, 50.3 ± 2.4%).
The high number of infiltrating immune cells
(Table 2) in these tumors indicated on important
mode of this therapeutic action; the highest and
statistically significantly increased number of immune cells was observed in the groups combinRadiol Oncol 2017; 51(1): 30-39.
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TABLE 2. Immunohistological analysis of tumors
Necrosis
(%)

Therapeutic group
AM

Apoptosis
(%)

Hypoxia
(%)

Proliferation
(%)

Vascularization
(n of structures)

Immune cells
(n of cells)

SEM

AM

SEM

AM

SEM

AM

SEM

AM

SEM

AM

CTRL

25.0

±

2.6

11.3

±

1.6

4.7

±

1.0

92.2

±

1.3

51.6

±

3.2

7.9

±

0.9

pControl

20.0

±

2.6

11.6

±

1.0

5.4

±

1.0

92.1

±

1.2

47.1

±

4.7

8.3

±

1.1

TS

21.7

±

2.6

11.4

±

1.5

5.5

±

0.7

92.7

±

1.0

50.5

±

4.2

7.9

±

0.7

3 × EP

13.3

±

3.6

18.7

±

2.7

7.8

±

0.8

74.4

±

1.7

39.9

±

2.6

14.3

±

1.7

3 × GET (pControl)

53.3

±

7.9

19.5

±

3.0

15.3

±

2.9

75.6

±

2.4

35.3

±

4.2

15.1

±

1.6

3 × GET (TS)

65.8

±

7.6

26.7

±

2.2

46.3

±

3.0

49.5

±

3.8

14.9

±

1.1

19.3

±

1.7

IR

21.7

±

4.2

18.4

±

1.8

30.2

±

2.4

53.3

±

3.5

30.1

±

2.3

26.8

±

2.6

pControl + IR

37.5

±

8.0

18.7

±

1.9

32.3

±

2.5

54.5

±

4.7

24.5

±

1.8

26.4

±

2.1

TS + IR

43.3

±

8.0

19.9

±

1.5

31.6

±

2.3

52.0

±

2.9

23.8

±

1.6

26.4

±

2.3

3 × EP + IR

25.0

±

4.8

31.0

±

2.0

51.7

±

2.6

59.4

±

4.0

28.9

±

2.3

29.3

±

2.1

3 × GET (pControl) + IR 65.0

±

7.6

38.7

±

3.1

58.0

±

2.8

46.0

±

4.8

18.9

±

2.0

45.8

±

3.0

3 × GET (TS) + IR

±

4.2

50.3

±

2.4

66.7

±

1.6

46.7

±

4.8

12.8

±

1.0

46.5

±

2.1

79.2

SEM

AM = Arithmetic mean; Groups: (CTRL = control; EP = electric pulses; GET = gene electrotransfer; IR = irradiation; TS = pET-antiCD105); n = Number of structures or cells; SEM = Standard error

ing GET of plasmids and irradiation, followed by
all the remaining groups that included irradiation
(alone, TS, pControl and 3 × EP). In these groups,
the immune cells infiltration was comparable and
statistically significant to all of the other remaining
groups. Furthermore, the immune cells infiltration
was the lowest in the groups that included electric
pulses (alone or with plasmids alone). Additionally,
all of the mice that were tumor free after the therapies including irradiation, either alone or in combination with other modalities, had fur discoloration,
known as vitiligo, indicating immune response
(Figure 2). This was further confirmed with high
number of mice that were resistant to secondary
challenge in tumor free mice, with the exception of
the group combining electric pulses and irradiation
(Table 1). In these groups, in which tumors grew after secondary challenge, the growth rate and histology of the tumors were the same as after the initial
induction of tumors (data not shown).
In addition, the safety of the treatment (irradiation alone or in combination with other modalities)
was proven, since no body weight loss over 10%, or
any other side effects were observed, except for the
temporary hair loss in the irradiated area, without
skin desquamation (data not shown).

Discussion
The results of this study indicate a dual effect of
GET of plasmid encoding shRNA for silencing
Radiol Oncol 2017; 51(1): 30-39.

endoglin, the direct and the indirect, both having
a radiosensitizing effect. The direct effect was on
the tumor vasculature and also on melanoma tumor cells, whereas the indirect was observed with
the use of plasmid devoid of therapeutic gene,
through boosting the immune response in tumors.
Furthermore, irradiation had mainly affected melanoma cells, although some effect on vasculature
could also be noticed. In addition, the higher number of infiltrating immune cells in all of the groups
combined with irradiation indicated an important
role of the immune system. All of these effects had
synergistic action and, in combined treatment modality of GET and irradiation, resulted in increased
radiosensitizing effectiveness of melanoma tumors
that resulted in prolonged tumor growth delay,
which led to 88% of tumor free mice, of which 57%
were resistant to secondary challenge of tumors.

Dual effectiveness of GET
The first direct effect of GET (TS) was on tumor
vasculature, which was significantly reduced after
the treatment. This vascular effect can be ascribed
to the specificity of the plasmid for endothelial cells
and to the endoglin silencing. This direct effect on
tumor vasculature was also observed in other studies using GET of plasmid for silencing endoglin on
melanoma22,23 and other tumor models.18,19,21 The
vascular targeted effects in these studies were first
confirmed in non-endoglin expressing tumors, i.e.
murine mammary adenocarcinoma, by endotheli-
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al-specific promoter18,21 and non-specific, constitutive promoter18–21, that resulted in pronounced antitumor effectiveness. In melanoma tumor model,
B16F10-luc, the GET of plasmids silencing endoglin resulted in significant antimetastatic effectiveness.22 Furthermore, GET of plasmid silencing
endoglin, with constitutive promoter, performed
on small melanoma B16F10 tumor model (4 mm3
at the beginning of therapy) confirmed vascular
targeted effects, which resulted in prolonged tumor growth delay and tumor free mice (58%), also
due to nonspecific nature of constitutive plasmid
that was used in this study silenced endoglin also
in melanoma cells.23 Nevertheless, in the current
study, which was done on bigger tumors (40 mm3),
in addition to significant increased level of hypoxia, also decreased number of proliferating tumor
cells was observed. This was attributed to the second direct effect of GET (TS), that is silencing of
endoglin also in melanoma cells, since it is known
that plasmid with tissue specific promoters can be
leaky and can also be transcribed in non-targeted
tissue.27 Therefore, GET (TS) has dual direct effects;
primarily by targeting vasculature and secondly by
inhibition of proliferation of melanoma cells. These
two effects together resulted in 44% of tumor free
mice, from which 75% were resistant to secondary
challenge of tumor cells.
Nevertheless, high level of infiltrating immune
cells in the tumors, indicated also an indirect effect of this treatment, through the stimulation of
immune response. This is also supported by the
data obtained with GET of the plasmid devoid of
therapeutic gene (pControl). In comparison to GET
of therapeutic plasmid, TS, no tumor cures were
obtained, however, in other measured parameters,
infiltration of immune cells into the tumors, levels of necrosis and apoptosis as well as in tumor
growth delay no statistically significant differences were obtained between these groups. Thus, to
a certain degree, a similar mode of antitumor action can be ascribed to the GET of plasmid DNA,
mainly because the values of these parameters
were statistically different from pertinent control
groups. Antitumor effectiveness of GET of nontherapeutic (control) plasmids was also observed
in other studies9,10, and the authors indicated that
effectiveness was due to involvement of immune
system. Namely, the plasmid introduced during
GET can act as a DAMP that is recognized through
different sensors (Pattern Recognition Receptors),
leading to the activation of the signal transduction
cascade that ultimately triggers the production
of type 1 interferons and other cytokines.28 These

act as a link between the innate and adaptive immune response29 and can induce the adaptive immune response against the introduced DNA and
consequently the transfected cells. Furthermore,
similar immune response can also be triggered by
the stress30 that is produced during the transfection
procedure, like mechanical stress, heat, and ROS,
that have all been previously reported after electroporation.31,32

Priming effect of irradiation
To target primary tumors, as was done in this
study, irradiation is one of the most used treatment
modalities.33 This therapeutic approach alone or
in combination with injection of plasmids, in radioresistant melanoma tumor model, resulted in
moderate tumor growth delay, which was attributed to decreased proliferation of melanoma cells,
increased levels of apoptosis and necrosis. Further
histological analysis indicated on the radiation
damage of the tumor vasculature, as a second effect of the irradiation, as seen in other studies.34,35
This vascular damage was less pronounced than in
group of GET (TS), although in comparison to GET
(TS), irradiation monotherapy resulted in higher infiltration of the immune cells in the tumors.
Furthermore, in the group combining irradiation
and injection of therapeutic plasmid, one mouse
was tumor free, which was also resistant to secondary challenge of tumor. This indicates a priming effect of irradiation combined with introduction of foreign DNA, through boosting the immune
response. When irradiated cells die, they release
their antigens in the context of the danger signal
(DAMPS), which result in the priming of a tumor
specific immune response against the released antigens. Therefore, irradiated tumors can sometimes
act as a powerful individualized in situ vaccine13,
which is manifested as the abscopal effect of the irradiation. This was confirmed in in vivo studies indicating that irradiation can induce in vivo priming
of T cells to exogenous model antigens engineered
to be expressed by tumors.13 In melanoma tumor
model, priming of antitumor T cells to the model
antigen ovalbumin, was more effective when single, 15 Gy dose was used, rather than 3 Gy given in
5 consecutive days.36 Further on, another group also showed induction of antitumor T-cell responses
with other antigen expression, when single 20 Gy
dose was applied, but not by 5 Gy given 4 times.37
The combination of electric pulses and irradiation exerted moderate antitumor effectiveness that
resulted in 22% of tumor free mice. Similar results
Radiol Oncol 2017; 51(1): 30-39.
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were obtained in our previous studies on murine mammary adenocarcinoma18, sarcoma17 and
Ehrlich-Lettre ascites38, where also 20%, 27% and
54% of tumor free mice were observed, respectively. Therefore we can assume that electroporation of
tumors contributes to radioresponsiveness of melanoma, most probably due to generation of ROS32,39
after application of the electric pules, which also resulted in significantly elevated levels of hypoxia in
our histological analysis.

Immune boosting and radiosensitization
by plasmid DNA
The combined treatment modalities (combination
of GET (TS or pControl) with irradiation) exerted
excellent, highly statistically significant antitumor
effect in comparison to control groups, which resulted in 88% and 89% of tumor free mice, respectively, of which 57% and 63% of mice were resistant to secondary challenge of tumors, respectively.
The results of histological analysis were similar
between groups of combined treatment modality
(GET + IR), regardless of the applied plasmid. The
only two differences were on the levels of apoptosis and hypoxia. The analysis of the presence of
the immune cells showed on the highest number of
the immune cells in the groups of GET of plasmids
and irradiation, followed by irradiation groups
(alone or combined with injections of plasmids or
combined with electric pulses). Therefore, it can be
presumed that the priming effect of irradiation can
be boosted by GET of the plasmid DNA to fully exert vaccinating effect. Additionally, fur discoloration, vitiligo, an immune-mediated destruction of
normal melanocytes that has also been recognized
as a positive prognostic indicator for treatment response40,41, was also observed in this study in all
the groups where tumor free mice were observed
(except 3 × GET (TS)). In addition, majority of the
tumor free mice were resistant to secondary challenge of tumors, further indicating on the development of the immune memory. The tumors in experimental groups, which were resistant to secondary
challenged of tumor, were therefore radiosensibilized through GET of plasmid, since in the group
combining electric pulses and irradiation, no mice
resulted resistant to secondary challenge of tumor.
The GET of plasmids in combination with irradiation presumably generated many danger signals
that collectively define immunogenic cell death.13
Furthermore, the immunogenicity of tumor
might also play an important role in combined
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treatment modality.42 In the current study we obtained significant antitumor effectiveness and up
to 89% of tumors free mice, that were up to 63%
resistant to secondary challenge of tumors, when
combining GET and irradiation in melanoma tumor model. Furthermore, in our previous study
combining the same treatment modality on a different tumor model, murine mammary adenocarcinoma TS/A, we achieved up to 44% of tumors
free mice with therapeutic plasmid silencing endoglin and 20% tumor free mice with the control
plasmid.18 We can presume that the boosting of
immune response depends on the tumor type,
melanoma being more immunogenic that mammary adenocarcinoma TS/A. Nevertheless, the
mechanisms of these therapies are not fully elucidated. Currently, we presume that there is involvement of DNA sensors, ROS and specific immune response after irradiation, but further studies are needed.

Conclusions
The results of this study indicate that irradiation
can in radioresistant mice tumors, such as melanoma, by release of tumor associated antigens
serve as the target of the immune response. This
can be further boosted by GET of plasmid, with or
without therapeutic gene, which was confirmed by
the equal radiosensitization resulting in prolonged
tumor growth delay and up to 89% of tumor free
mice, which kept immune memory to melanoma
cells. In addition, GET of therapeutic plasmid silencing endoglin has also direct effect on vasculature and tumors cells; however in combination
with radiotherapy this effect was masked by pronounced immune response.
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